局部晚期非小细胞肺癌根治性放化疗联合巩固免疫检查点抑制剂治疗后的失败模式、低体积复发及后续消融治疗管理
本研究回顾性分析单机构2017年10月至2021年12月连续229例接受根治性放化疗联合巩固免疫检查点抑制剂治疗的III期非小细胞肺癌患者,描述失败模式、低体积复发频率及进展时消融治疗候选资格。119例(52%)出现疾病进展,其中64例(54%)为低体积复发,60例(50%)符合消融治疗条件;低体积复发与更长的进展后生存相关(中位37.4 vs 15.2个月,P < .001)。
要点
- 229例III期非小细胞肺癌患者中119例(52%)出现疾病进展,64例(54%)为低体积复发。
- 进展时60例(50%)符合消融治疗条件,低体积复发中位生存37.4个月 vs 高体积复发15.2个月(P < .001)。
- 多变量分析显示低体积复发与进展后生存改善相关(HR 0.32,95%CI 0.18-0.56,P < .001)。
核心结论
- 放化疗联合巩固免疫检查点抑制剂治疗后,约半数患者在疾病进展时表现为低体积复发并符合消融治疗条件。
- 低体积复发与更长的进展后生存相关(中位37.4 vs 15.2个月,P < .001;HR 0.32,95%CI 0.18-0.56,P < .001)。
- 需要前瞻性试验来验证低体积复发的最佳治疗策略。
研究设计与样本
- 单机构回顾性研究,纳入2017年10月至2021年12月连续229例接受根治性放化疗联合巩固免疫检查点抑制剂治疗的III期非小细胞肺癌患者。
- 疾病进展分为孤立性局部区域失败、孤立性远处失败或同时性局部区域失败+远处失败;局部区域失败进一步分为野内、边缘或野外失败。
- 低体积复发定义为任何器官中疾病进展部位≤3个;消融候选定义为影像学上适合高剂量放疗或手术的疾病进展部位≤5个。
- 采用累积发生率分析和Kaplan-Meier法计算时间-事件数据,多变量Cox模型分析复发特征与进展后生存的相关性。
主要发现
- 229例患者中119例(52%)出现疾病进展;其中20例(21%)为孤立性局部区域失败,28例(24%)为同时性局部区域失败+远处失败,71例(60%)为孤立性远处失败。
- 48例任何局部区域失败患者中,28例(58%)为野内失败,10例(21%)为边缘失败,10例(21%)为野外失败。
- 局部区域失败和远处失败的累积发生率在1年分别为13%(95%CI 9.2%-18%)和32%(95%CI 26%-38%),在2年分别为19%(95%CI 14%-24%)和39%(95%CI 33%-46%)。
- 总体64例(54%)被认定为低体积复发;疾病进展时60例(50%)符合消融治疗条件。
- 低体积复发患者中位生存37.4个月 vs 高体积复发患者15.2个月(P < .001);多变量分析中低体积复发与进展后生存改善相关(HR 0.32,95%CI 0.18-0.56,P < .001)。
关键数值与推荐
- 低体积复发定义为任何器官中疾病进展部位≤3个。
- 消融候选定义为影像学上适合高剂量放疗或手术的疾病进展部位≤5个。
- 疾病进展分类:孤立性局部区域失败、孤立性远处失败或同时性局部区域失败+远处失败;局部区域失败 subclassified 为野内、边缘或野外失败。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective of this study was to describe the patterns of failure, frequency of low-volume relapse (LVR), and candidacy for ablative therapy at time of disease progression (PD) after chemoradiation and consolidative immunotherapy (CRT + ICI) in patients with stage III non-small cell lung cancer. METHODS AND MATERIALS: We identified 229 consecutive patients with stage III non-small cell lung cancer treated with CRT + ICI between October 2017 and December 2021 at a single institution. PD was classified as isolated locoregional failure (LRF), isolated distant failure (DF), or synchronous LRF + DF. Any LRF was subclassified as in-field failure, marginal failure, or out-of-field failure. LVR was defined as 3 or fewer sites of PD in any number of organs. Ablative candidates were defined as having 5 or fewer sites of PD radiographically amenable to high-dose radiation or surgery. Time-to-event data were calculated using cumulative incidence analysis and Kaplan-Meier methods. Multivariable Cox modeling was used to examine the correlations between characteristics of relapse and postprogression survival. RESULTS: Of the 229 patients, 119 (52%) had PD. Of these 119 patients, 20 (21%) had isolated LRF, 28 (24%) had synchronous LRF + DF, and 71 (60%) had isolated DF. Of the 48 patients with any LRF, 28 (58%) had in-field failure, 10 (21%) marginal failure, and 10 (21%) out-of-field failure. The cumulative incidence of LRF and DF was 13% (95% CI, 9.2%-18%) and 32% (95% CI, 26%-38%) at 1 year and 19% (95% CI, 14%-24%) and 39% (95% CI, 33%-46%) at 2 years, respectively. Overall, 64 patients (54%) were considered to have LVR. At time of PD, 60 patients (50%) were eligible for ablative therapy. Patients with LVR had longer median survival versus with high-volume relapse (37.4 vs 15.2 months, P < .001). On multivariable analysis, LVR (hazard ratio, 0.32; 95% CI, 0.18-0.56; P < .001) was associated with improved postprogression survival. CONCLUSIONS: After CRT + ICI, approximately half of patients experience LVR at time of PD and are candidates for ablative therapies. Prospective trials are needed to validate the optimal treatment strategy for LVR.
引用
- Friedes C, Iocolano M, Lee SH, et al. Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2023. PMID: 37866762. doi:10.1016/j.ijrobp.2023.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。